Tissue Regenix Group plc
TSSNF
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $9.23 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 1.43 |
| Outstanding Shares | 70,603,015 |
Return
| Return on Equity | -8.45% |
|---|---|
| Return on Assets | -5.55% |
| Return on Invested Capital | -1.27% |
Valuation & Multiples
| P/E Ratio | -7.09 |
|---|---|
| PEG | 10.23 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.2 |
| Enterprise Value to EBIT | -18.57 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 1.2 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Tissue Regenix Group Plc
CEO: Daniel R. Lee Tissue Regenix Group Plc is a medical technology company, which develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine. It operates through BioSurgery, Orthopaedics & Dental, Cardia...